Studio Wildcard says it can shrug its reputation for missed deadlines and massively enhance Ark Survival Ascended with its ...

Here's a complete list of every material and the amount you need to complete the Season 2 Expedition in Arc Raiders.

Following closing, combined company plans to progress Yarrow’s lead program, YB-101, a potentially first-in-class anti-thyroid-stimulating hormone receptor (“TSHR”) antibody for Graves’ disease (“GD”) ...

Vyne Therapeutics is set to combine with Yarrow Bioscience in an all-stock merger. Vyne, a clinical-stage biopharmaceutical company, and Yarrow Bioscience, a clinical-stage biotechnology company said ...

The MarketWatch News Department was not involved in the creation of this content. -- Collaboration to focus on building a leading, US-based biotech dedicated to addressing underserved patients ...

U.S.-based Yarrow Bioscience is branching out, picking an autoimmune thyroid disease drug from China as its lead candidate. Through a potential $1.37 billion deal, New York-headquartered Yarrow gains ...

Collaboration to focus on building a leading, US-based biotech dedicated to addressing underserved patients impacted by autoimmune and endocrinology disorders GenSci to receive $70 million ...

Shanghai Scizeng Medical Technology Co., LTD, a subsidiary of Changchun GeneScience Pharmaceutical Co., Ltd. (“GenSci”), RTW Investments, LP (“RTW”), and Yarrow Bioscience, Inc. (“Yarrow”) today ...